Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial
Background Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).Objective This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments.Methods...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis Group
2025-12-01
|
| Schriftenreihe: | Journal of Dermatological Treatment |
| Schlagworte: | |
| Online-Zugang: | https://www.tandfonline.com/doi/10.1080/09546634.2025.2591478 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|
